Top

Published in:

Open Access 01-12-2021 | Parkinson's Disease | Original Article

Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease

Authors: Minkyeong Kim, Seulki Yoo, Doyeon Kim, Jin Whan Cho, Ji Sun Kim, Jong Hyun Ahn, Jun Kyu Mun, Inyoung Choi, Seung-Kyun Lee, Jinyoung Youn

Published in: Neurological Sciences | Issue 12/2021

Abstract

Background

Although iron dyshomeostasis is associated with Parkinson’s disease (PD) pathogenesis, the relationship between iron deposition and non-motor involvement in PD is not fully understood. In this study, we investigated basal ganglia and extra-basal ganglia system iron contents and their correlation with non-motor symptoms in drug-naïve, early-stage PD patients.

Methods

We enrolled 14 drug-naïve, early-stage PD patients and 12 age/sex-matched normal controls. All participants underwent brain magnetic resonance imaging to obtain the effective transverse relaxation rate (R2*) and quantitative susceptibility mapping (QSM). Deep brain structures, including the nucleus accumbens, caudate nucleus, putamen, globus pallidus, thalamus, hippocampus, and amygdala, were delineated using the FSL-FIRST; the substantia nigra, red nucleus, and dentate nucleus were segmented manually. Inter-group differences in R2* and QSM values, as well as their association with clinical parameters of PD, were investigated.

Results

Substantia nigra and putamen R2* values were significantly higher in PD patients than in normal controls, despite no significant difference in QSM values. Regarding the non-motor symptom scales, PD sleep scale score negatively correlated with R2* values in the red nucleus and right amygdala, Scales for Outcomes in Parkinson’s disease-Autonomic scores were positively correlated with R2* values in the right amygdala and left hippocampus, and cardiovascular sub-score of Non-Motor Symptoms Scale for PD was positively associated with the QSM value in the left hippocampus.

Conclusion

In this study, iron content in the extra-basal ganglia system was significantly correlated with non-motor symptoms, especially sleep problems and dysautonomia, even in early-stage PD.

Available only for authorised users

Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13(10):1045–1060. https://doi.org/10.1016/S1474-4422(14)70117-6CrossRefPubMedPubMedCentral

Surendran S, Rajasankar S (2010) Parkinson’s disease: oxidative stress and therapeutic approaches. Neurol Sci 31(5):531–540. https://doi.org/10.1007/s10072-010-0245-1CrossRefPubMed

Telling ND, Everett J, Collingwood JF, Dobson J, van der Laan G, Gallagher JJ, Wang J, Hitchcock AP (2017) Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer's disease. Cell Chem Biol 24(10):1205–1215.e1203. https://doi.org/10.1016/j.chembiol.2017.07.014CrossRefPubMed

Ong WY, Farooqui AA (2005) Iron, neuroinflammation, and Alzheimer’s disease. J Alzheimers Dis 8(2):183–200; discussion 209-115. https://doi.org/10.3233/jad-2005-8211CrossRefPubMed

Wang J-Y, Zhuang Q-Q, Zhu L-B, Zhu H, Li T, Li R, Chen S-F, Huang C-P, Zhang X, Zhu J-H (2016) Meta-analysis of brain iron levels of Parkinson’s disease patients determined by postmortem and MRI measurements. Sci Rep 6:36669. https://doi.org/10.1038/srep36669CrossRefPubMedPubMedCentral

Pietracupa S, Martin-Bastida A, Piccini P (2017) Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review. Neurol Sci 38(12):2095–2101. https://doi.org/10.1007/s10072-017-3099-yCrossRefPubMed

Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S, Homayoon N, Katschnig-Winter P, Koegl-Wallner M, Pendl T, Stoegerer EM, Wenzel K, Fazekas F, Ropele S, Reichenbach JR, Schmidt R, Schwingenschuh P (2016) Quantitative susceptibility mapping in Parkinson’s disease. PLoS One 11(9):e0162460. https://doi.org/10.1371/journal.pone.0162460CrossRefPubMedPubMedCentral

Du G, Lewis MM, Sica C, He L, Connor JR, Kong L, Mailman RB, Huang X (2018) Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson’s patients. Mov Disord 33(9):1423–1431. https://doi.org/10.1002/mds.27318CrossRefPubMedPubMedCentral

Uchida Y, Kan H, Sakurai K, Arai N, Kato D, Kawashima S, Ueki Y, Matsukawa N (2019) Voxel-based quantitative susceptibility mapping in Parkinson’s disease with mild cognitive impairment. Mov Disord 34(8):1164–1173. https://doi.org/10.1002/mds.27717CrossRefPubMed

10.

Thomas GEC, Leyland LA, Schrag A-E, Lees AJ, Acosta-Cabronero J, Weil RS (2020) Brain iron deposition is linked with cognitive severity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 91(4):418–425. https://doi.org/10.1136/jnnp-2019-322042CrossRefPubMed

11.

Shin C, Lee S, Lee JY, Rhim JH, Park SW (2018) Non-motor symptom burdens are not associated with iron accumulation in early Parkinson’s disease: a quantitative susceptibility mapping study. J Korean Med Sci 33(13):e96. https://doi.org/10.3346/jkms.2018.33.e96CrossRefPubMedPubMedCentral

12.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424CrossRefPubMed

13.

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442. https://doi.org/10.1212/wnl.17.5.427CrossRefPubMed

14.

Fahn S ER (1987) UPDRS program members. In: Fahn S, Marsden CD, Goldstein M, CalneDB, editors Unified Parkinson’s disease rating scale. Recent developments in Parkinson’s disease vol. 2. p153–163, 293–304

15.

Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG (2003) Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 60(4):529–533. https://doi.org/10.1001/archneur.60.4.529CrossRefPubMed

16.

Yook SKZ (1997) A clinical study on the Korean version of Beck anxiety inventory: comparative study of patient and non-patient. Korean J Clin Psychol 16(1):185–197

17.

Choi SH, Na DL, Kwon HM, Yoon SJ, Jeong JH, Ha CK (2000) The Korean version of the neuropsychiatric inventory: a scoring tool for neuropsychiatric disturbance in dementia patients. J Korean Med Sci 15(6):609–615. https://doi.org/10.3346/jkms.2000.15.6.609CrossRefPubMedPubMedCentral

18.

Brown RG, Dittner A, Findley L, Wessely SC (2005) The Parkinson fatigue scale. Parkinsonism Relat Disord 11(1):49–55. https://doi.org/10.1016/j.parkreldis.2004.07.007CrossRefPubMed

19.

J S, Baik JYK, Park JH (2005) Parkinson’s disease sleep scale in Korea. J Korean Neurol Assoc 23(1):41–48

20.

Frauscher B, Ehrmann L, Zamarian L, Auer F, Mitterling T, Gabelia D, Brandauer E, Delazer M, Poewe W, Hogl B (2012) Validation of the Innsbruck REM sleep behavior disorder inventory. Mov Disord 27(13):1673–1678. https://doi.org/10.1002/mds.25223CrossRefPubMed

21.

Kim J-Y, Song I-U, Koh S-B, Ahn T-B, Kim SJ, Cheon S-M, Cho JW, Kim YJ, Ma H-I, Park M-Y, Baik JS, Lee PH, Chung SJ, Kim J-M, Kim H-J, Sung Y-H, Kwon DY, Lee J-H, Lee J-Y, Kim JS, Yun JY, Kim HJ, Hong JY, Kim M-J, Youn J, Kim JS, Oh ES, Yang H-J, Yoon WT, You S, Kwon K-Y, Park H-E, Lee S-Y, Kim Y, Kim H-T, Kim J-S (2017) Validation of the Korean version of the scale for outcomes in Parkinson’s disease-autonomic. JMD 10(1):29–34. https://doi.org/10.14802/jmd.16057CrossRefPubMedPubMedCentral

22.

Koh SB, Kim JW, Ma HI, Ahn TB, Cho JW, Lee PH, Chung SJ, Kim JS, Kwon DY, Baik JS (2012) Validation of the Korean-version of the nonmotor symptoms scale for Parkinson’s disease. JCN 8(4):276–283. https://doi.org/10.3988/jcn.2012.8.4.276CrossRef

23.

LE Lim SY, Jeong SW, Kim HC, Jeong CH, Jeon TY et al (2011) The validation study of Beck depression scale 2 in Korean version. Anxiety Mood 7:43–53

24.

Kim JI, Sunwoo MK, Sohn YH, Lee PH, Hong JY (2016) The MMSE and MoCA for screening cognitive impairment in less educated patients with Parkinson’s disease. JMD 9(3):152–159. https://doi.org/10.14802/jmd.16020CrossRefPubMedPubMedCentral

25.

Gudbjartsson H, Patz S (1995) The Rician distribution of noisy MRI data. Magn Reson Med 34(6):910–914. https://doi.org/10.1002/mrm.1910340618CrossRefPubMedPubMedCentral

26.

Gho SM, Liu C, Li W, Jang U, Kim EY, Hwang D, Kim DH (2014) Susceptibility map-weighted imaging (SMWI) for neuroimaging. Magn Reson Med 72(2):337–346. https://doi.org/10.1002/mrm.24920CrossRefPubMed

27.

Nioche C, Cabanis EA, Habas C (2009) Functional connectivity of the human red nucleus in the brain resting state at 3T. AJNR 30(2):396–403. https://doi.org/10.3174/ajnr.A1375CrossRefPubMedPubMedCentral

28.

Colpan ME, Slavin KV (2010) Subthalamic and red nucleus volumes in patients with Parkinson’s disease: Do they change with disease progression? Parkinsonism Relat Disord 16(6):398–403. https://doi.org/10.1016/j.parkreldis.2010.03.008CrossRefPubMed

29.

Enatsu R, Gonzalez-Martinez J, Bulacio J, Kubota Y, Mosher J, Burgess RC, Najm I, Nair DR (2015) Connections of the limbic network: a corticocortical evoked potentials study. Cortex 62:20–33. https://doi.org/10.1016/j.cortex.2014.06.018CrossRefPubMed

30.

Jhe N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z, Liu C, Chen K, Yan F (2015) Region-specific disturbed iron distribution in early idiopathic Parkinson’s disease measured by quantitative susceptibility mapping. Hum Brain Mapp 36(11):4407–4420. https://doi.org/10.1002/hbm.22928CrossRef

31.

Du G, Liu T, Lewis MM, Kong L, Wang Y, Connor J, Mailman RB, Huang X (2016) Quantitative susceptibility mapping of the midbrain in Parkinson’s disease. Mov Disord 31(3):317–324. https://doi.org/10.1002/mds.26417CrossRefPubMed

32.

Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T (2019) Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease. Mov Disord 34(7):1006–1013. https://doi.org/10.1002/mds.27730CrossRefPubMedPubMedCentral

33.

Aquino D, Contarino V, Albanese A, Minati L, Farina L, Grisoli M, Elia A, Bruzzone MG, Chiapparini L (2014) Substantia nigra in Parkinson’s disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 35(5):753–758. https://doi.org/10.1007/s10072-013-1595-2CrossRefPubMed

34.

Liu Z, Shen H-C, Lian T-H, Mao L, Tang S-X, Sun L, Huang X-Y, Guo P, Cao C-J, Yu S-Y, Zuo L-J, Wang X-M, Chen S-D, Chan P, Zhang W (2017) Iron deposition in substantia nigra: abnormal iron metabolism, neuroinflammatory mechanism and clinical relevance. Sci Rep 7(1):14973–14973. https://doi.org/10.1038/s41598-017-14721-1CrossRefPubMedPubMedCentral

35.

Li X, Xing Y, Schwarz ST, Auer DP (2017) Limbic grey matter changes in early Parkinson’s disease. Hum Brain Mapp 38(7):3566–3578. https://doi.org/10.1002/hbm.23610CrossRefPubMedPubMedCentral

36.

Kalaitzakis ME, Gentleman SM, Pearce RK (2013) Disturbed sleep in Parkinson’s disease: anatomical and pathological correlates. Neuropathol Appl Neurobiol 39(6):644–653. https://doi.org/10.1111/nan.12024CrossRefPubMed

37.

Yoo SW, Yun E, Bang M, Yoon U, Yoo JY, Lee KS, Shin NY, Kim JS (2020) Blood pressure lability is associated with subcortical atrophy in early Parkinson’s disease. J Hypertens 38(10):2043–2049. https://doi.org/10.1097/hjh.0000000000002505CrossRefPubMed

38.

Wang Y, Liu T (2015) Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker. Magn Reson Med 73(1):82–101. https://doi.org/10.1002/mrm.25358CrossRefPubMed

39.

Rua C, Clarke WT, Driver ID, Mougin O, Morgan AT, Clare S, Francis S, Muir KW, Wise RG, Carpenter TA, Williams GB, Rowe JB, Bowtell R, Rodgers CT (2020) Multi-centre, multi-vendor reproducibility of 7T QSM and R(2)* in the human brain: Results from the UK7T study. Neuroimage 223:117358. https://doi.org/10.1016/j.neuroimage.2020.117358CrossRefPubMed

40.

Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schäfer A, Peters AM, Bowtell RW, Auer DP, Gowland PA, Bajaj NP (2012) High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease. J Magn Reson Imaging 35(1):48–55. https://doi.org/10.1002/jmri.22752CrossRefPubMed

Title: Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease
Authors: Minkyeong Kim
Seulki Yoo
Doyeon Kim
Jin Whan Cho
Ji Sun Kim
Jong Hyun Ahn
Jun Kyu Mun
Inyoung Choi
Seung-Kyun Lee
Jinyoung Youn
Publication date: 01-12-2021
Publisher: Springer International Publishing
Keyword: Parkinson's Disease
Published in: Neurological Sciences / Issue 12/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05223-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2021

p.Asn1180Ile mutation of SCN4A gene in an Italian family with myopathy and myotonic syndrome

What might cervical vestibular–evoked myogenic potential abnormalities mean in essential tremor?

High-resolution ultrasound changes of the vagus nerve in idiopathic Parkinson’s disease (IPD): a possible additional index of disease

Face pareidolia is associated with right striatal dysfunction in drug-naïve patients with Parkinson’s disease

Neurological manifestations of COVID-19 in patients: from path physiology to therapy

SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature